| Literature DB >> 11689848 |
M Ramachandra1, A Rahman, A Zou, M Vaillancourt, J A Howe, D Antelman, B Sugarman, G W Demers, H Engler, D Johnson, P Shabram.
Abstract
Replicating adenoviruses may prove to be effective anticancer agents if they can be engineered to selectively destroy tumor cells. We have constructed a virus (01/PEME) containing a novel regulatory circuit in which p53-dependent expression of an antagonist of the E2F transcription factor inhibits viral replication in normal cells. In tumor cells, however, the combination of p53 pathway defects and deregulated E2F allows replication of 01/PEME at near wild-type levels. The re-engineered virus also showed significantly enhanced efficacy compared with extensively studied E1b-deleted viruses such as dl1520 in human xenograft tumor models.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11689848 DOI： 10.1038/nbt1101-1035
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908